By Connor Hart

 

Novavax Inc. on Friday said the Korea Ministry of Food and Drug Safety approved partner SK Bioscience's Covid-19 vaccine for adolescents aged 12 through 17 in South Korea.

The Gaithersburg, Md.-based biotech company said the approval was based on data from ongoing pediatric trials across 73 sites in the U.S.

Preliminary safety data from the trial showed the vaccine to be generally well-tolerated, and adverse events were low in number and balanced between vaccine and placebo groups not considered related to the vaccine, the company said.

In the 12 through 17 year-old population, the Novavax's vaccine has been granted authorization in India, the European Union, Australia, Thailand, and Japan, and is actively under review in other markets, the company said.

 

Write to Connor Hart at connor.hart@wsj.com

 

(END) Dow Jones Newswires

August 12, 2022 09:55 ET (13:55 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.
Novavax (NASDAQ:NVAX)
Historical Stock Chart
From Sep 2022 to Oct 2022 Click Here for more Novavax Charts.
Novavax (NASDAQ:NVAX)
Historical Stock Chart
From Oct 2021 to Oct 2022 Click Here for more Novavax Charts.